Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02432235 (Clinical Trial/ ADCT-301)

Study Title
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT02432235)

Trial Description
This study evaluates ADCT-301 in patients with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma. Patients will participate in a dose-escalation phase (Part 1) and receive escalating doses of ADCT-301 every 3 weeks. In Part 2 of the study, patients will receive a recommended dose of ADCT-301 every 3 weeks.
This trial is sponsored by ADC Therapeutics SARL. [1]

Study Data

  • Condition: 
    • Hodgkin Lymphoma
    •  Non-Hodgkin Lymphoma
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 140
  • Start: June 2015
  • Estimated Primary Completion: June 2018
  • Last updated: October 2017

Study Schematic

Click here to Return to Drug map


Last Editorial review: January 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2018 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar